Pharmacokinetics: Digoxin Allie Punke

Slides:



Advertisements
Similar presentations
Clinical Pharmacokinetics
Advertisements

Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
Pharmacokinetics Questions
Nonlinear pharmacokinetics
One-compartment open model: Intravenous bolus administration
Laplace transformation
Practical Pharmacokinetics
Inpatient Pharmacy Vivian Sinkaset, Pharm.D., BCPS Miramar Science Club Guest Speaker April 28, 2010.
Dose Adjustment in Renal and Hepatic Disease
INTRAVENOUS INFUSION.
Excretion of Drugs By the end of this lecture, students should be able to Identify main and minor routes of Excretion including renal elimination and biliary.
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Objective: Explain the variation in dosing intervals for medications 1)Introduce Half-Life (t 1/2 ) 2)Relate Half-Life to Dosing intervals of aspirin and.
Valproic Acid Software and Presentation by: Ted, Rob, Jeff, Cassie, Tristan, Korin, Ron, Gabe, Matt, Judith, Lindsay.
Summary Lecture Gout/Glaucoma Learning Outcomes Predict the activity of a drug based on its structure & physiochemical properties Demonstrate an understanding.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Digoxin ‘it has a power over the motion of the heart to a degree yet unobserved in any other medicine…’ Withering, 1775.
Pharmacology Department
1-Compartment Oral Dosing 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following.
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
BASIC PHARMACOLOGY 2 SAMUEL AGUAZIM(MD).
Core Concepts in Pharmacology Chapter 5 Pharmacokinetics.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Therapeutic Drug Monitoring (TDM) Sticker Project A New Method for Documenting Times of Medication Doses and Drug Levels.
Clinical Pharmacokinetics Fundamental hypothesis: a relationship exists between the pharmacological or toxic response to a drug and the accessible concentration.
1. Fate of drugs in the body 1.1 absorption 1.2 distribution - volume of distribution 1.3 elimination - clearance 2. The half-life and its uses 3. Repeated.
Continuous intravenous infusion (one-compartment model)
Excretion of Drugs By the end of this lecture, students should be able to Identify main and minor routes of Excretion including renal elimination and biliary.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
Prof. Dr. Henny Lucida, Apt
Therapeutic drug Monitoring
Clinical Pharmacokinetic Equations and Calculations
Case 9 Amikacin in an elderly CKD patient Block 9 : Divine Ramos, Remonte, Reyes, Rivera A, Rivera K, Rivera M, Rogelio, Sagayaga, Santiago, See, Siy,
Foundation Knowledge and Skills
ALLIE PUNKE PHARMACOKINETICS: ANTIEPILEPTIC DRUGS.
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
ALLIE PUNKE PHARMACOKINETICS: PSYCHOTROPIC DRUGS.
Pharmacokinetics: Warfarin
ALLIE PUNKE PHARMCOKINETICS. PHENYTOIN THE BASICS What is the volume of distribution: Regular floor patient: L/kg Critically ill patient: 0.8.
MULTIPLE DOSAGE REGIMEN
Allie punke Pharmacokinetics tutoring Fall 2016
Anticonvulsants: Phenytoin
Pharmacokinetics: psychotropic drugs
Allie punke Pharmacokinetics tutoring Fall 2016
Allie punke pharmcokinetics Allie punke
Pharmacokinetics: Pediatrics
Pharmacokinetics Tutoring
Lecture-8 Biopharmaceutics
Pharmacokinetics.
PHARMACOKINETICS Allie punke
Pharmacokinetics.
Pharmacokinetics: Warfarin
Pharmacokinetics.
Anticonvulsants: Valproic acid
Pharmacokinetics: Pediatrics
Pharmacokinetics.
Pharmacokinetics: Theophylline
Pharmacokinetics: immunosuppressive drugs
PHARMACOKINETICS Allie punke
Pharmcokinetics Allie punke.
Pharmcokinetics Allie punke.
Allie Punke Pharmacokinetics Allie Punke
Pharmcokinetics Allie punke.
Therapeutic Drug Monitoring chapter 1 part 1
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

Pharmacokinetics: Digoxin Allie Punke

The Basics What is the Volume of Distribution? What body weight should we use? Why? How is it eliminated? What is therapeutic range? Do we need to worry about protein binding interactions?

The Basics—True or False Most of the drug stays in the central compartment. The drug concentration closely correlates with the effect of digoxin. Digoxin should not recommended for a patient who requires acute control of heart rate. Your patient, who exercises 4-5 times a week, develops atrial fibrillation. Digoxin would be a reasonable recommendation in this patient. For pharmacokinetics purpose, we can assume a one compartment model.

Application—Half Life A male patient (56 years, 70 kg, 5’10”, Scr=1.1) is admitted to the hospital for digoxin toxicity. The level was 4 ng/ml. How long will it take for the digoxin level to decrease to 1 ng/ml if no interventions are made?

Application--Toxicity What are some symptoms you would expect the previous patient to be experiencing?

Application--LD A female patient (98kg, 5’6”) is in the hospital and needs to be loaded with digoxin for rate control secondary to atrial fibrillation. If a goal level of 1 ng/ml is targeted, what IV loading dose do you recommend?

Application--LD A female patient (98kg, 5’6”) is in the hospital and needs to be loaded with digoxin for rate control of her atrial fibrillation. If a goal level of 1 ng/ml is targeted, what oral loading dose do you recommend? F=0.7.

Application--MD A male patient (75 kg, 5’11”, SCr=1.3, 78 years old) has been loaded for rate control of his atrial fibrillation. If a goal level of 1 ng/ml is targeted, what maintenance do you recommend? F=0.7. A week later, he comes for a follow-up visit. He reports he feels “better” and has less shortness of breath throughout the day. His last dose was last night at 9 pm. Should we draw a digoxin level today? If so, when do you recommend drawing it?

Application--SDC SDC are indicated in patients who:

Application--Steady State A patient (60kg, 6’1”, Scr=1.2, 59 years old) has been receiving mg of digoxin. Today, his SDC is 0.5. A goal of 1 ng/ml is targeted. What do you recommend regarding his digoxin dose? F=0.9

Application--SDC A patient was loaded with digoxin at The SDC (drawn at 0600) was 3. The medical resident asks for you recommendation on how to manage this patient’s digoxin dosing. He wants to know how much you would recommend lowering the digoxin dose?

Application

Name the drug interaction: Antacids Verapamil ACEI + NSAID + diuretic Rifampin Amiodarone Bile acid sequestrants Antibiotics

Summary--Equations to Know LD (To get a level around 1.4 ng/ml) IV = ____ micrograms/kg IBW Oral= _____ micrograms/kg IBW Separated into ___ to ____ doses Maintenance Dose Digoxin clearance Adjusting a dose AT steady state

Summary--Equations to Know Estimating half-life of digoxin

Summary Remember the key equations to calculate LD and MD. Recognize common drug interactions and the mechanism of how they occur (affecting F/CL) Be able to clinically interpret a SDC. Remember the 3 major organs affected by toxicity and the symptoms they produce. Only get a SDC if it is indicated.

Questions? Good luck!